Table 2.
Counts, treatment times and therapeutic anticoagulation of CVVHD and SLEDD in COVID-19
| CVVHD | SLEDD | ||||
|---|---|---|---|---|---|
| UFH | Citrate | UFH | Argatroban | LMWH | |
| No. of RRT treatments | 13 | 92 | 22 | 27 | 76 |
| No. of patients | 7 | 18 | 9 | 3 | 7 |
| Total RRT duration, h | 274.7 | 4192.6 | 179.1 | 215.6 | 896.4 |
| Mean duration per RRT, h (SD) | 21.1 (20.2) | 45.6 (25.6) | 8.1 (6.2) | 8.0 (4.7) | 11.8 (4.7) |
| Early RRT termination, % | 92 | 55 | 64 | 67 | 30 |
| Therapeutic range, % | 81 | 98 | 100 | 96 | 78 |
Data reported as counts, mean values (standard deviation) and percentages. For the calculation of the percentage of early hemodialysis termination a minimum operating time per CVVHD treatment of at least 48 h was chosen. Percentages depict portion of treatments running less than 48 h. For the calculation of the percentage of early hemodialysis termination a minimum operating time per SLEDD treatment of at least 10 h was chosen. Percentages depict portion of treatments running less than 10 h. Percentage of aPTT-, post filter calcium, or anti-factor-Xa levels in therapeutic range (UFH: aPTT ≥45 s / 1.5 times baseline; citrate: ionized Ca2+ post filter < 0.35 mmol/L Argatroban: aPTT ≥45 s / 1.5 times baseline; LMWH ≥0.5 IU/mL)